Showing results (321-330 of 351) with videos related to

Sort By:
Pageof 36
Oncology|June 17, 2021
Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Overall Prognosis Following Lenvatinib TreatmentYusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
Clinical Journal of Gastroenterology|July 12, 2020
Undifferentiated carcinoma of the liver demonstrated by contrast-enhanced ultrasonographyNobuhiko Ogasawara, Satoshi Saitoh, Fumitaka Suzuki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 9, 2023
Treatment efficacy of diet and exercise program for fatty liver and pretreatment predictorsNorio Akuta, Yusuke Kawamura, Shunichiro Fujiyama, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 16, 2023
Impact of genetic polymorphism on personalized diet and exercise program for steatotic liver diseaseNorio Akuta, Yusuke Kawamura, Shunichiro Fujiyama, et al.
Internal Medicine (Tokyo, Japan)|May 6, 2026
Serum microRNA-122 Is Associated with the Therapeutic Response to Diet and Exercise Therapy in Patients with Steatotic Liver DiseaseYasuka Eriksson, Norio Akuta, Shigeki Yamamoto, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 30, 2012
Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patientsFumitaka Suzuki, Yoshiyuki Suzuki, Hitomi Sezaki, et al.
Internal Medicine (Tokyo, Japan)|September 23, 2020
Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with LenvatinibKayoko Kasuya, Yusuke Kawamura, Masahiro Kobayashi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 17, 2021
Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020Katsutoshi Tokushige, Kenichi Ikejima, Masafumi Ono, et al.
Journal of Gastroenterology|September 17, 2021
Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020Katsutoshi Tokushige, Kenichi Ikejima, Masafumi Ono, et al.
Internal Medicine (Tokyo, Japan)|September 13, 2021
Changes in the Mean Intrahepatic Target Computed Tomography Attenuation Value During Treatment May Be a Useful New Predictor of the Post-progression Survival Associated with Lenvatinib TreatmentNozomu Muraishi, Yusuke Kawamura, Masahiro Kobayashi, et al.
Pageof 36